Donato Amodio
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Donato Amodio has a total of 501 co-authors. Here are the top co-authors by number of shared publications:
- Paolo Palma
Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy
21 shared publications - Nicola Cotugno
Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy
17 shared publications - Veronica Santilli
Research Unit of Clinical Immunology and Vaccinology, Academic Department of Pediatrics (DPUO), IRCCS Bambino Gesù Children’s Hospital, 00165 Rome, Italy
9 shared publications - Caterina Cancrini
Research Unit of Primary Immunodeficiencies, Bambino Gesu’ Children’s Hospital, IRCCS, Italy
8 shared publications Veronica Santilli
Clinical Immunology and Vaccinology Unit Bambino Gesù Children's Hospital IRCCS Rome Italy
8 shared publications- Alessandra Ruggiero
Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy
6 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by MDPI AG in Preprints.org
Use of Dupilumab in Pediatric Atopic Dermatitis and in Inborn Errors of Immunity-Associated Atopic Skin Disease: An Italian Society of Pediatric Research (SIRP) Multicenter Real-World Study
Background: Atopic dermatitis (AD) is generally considered polygenic but may occur as a predominant manifestation of inborn errors of immunity (IEI). Although dupilumab is effective in pediatric AD, evidence in IEI-associated severe atopic skin disease remains limited, with no longitudinal comparative studies available. We aimed to characterize clinical phenotype and compare effectiveness, quality-of-life, and safety of dupilumab in pediatric patients with severe polygenic AD and IEI-associated severe atopic skin disease. Methods: This multicenter retrospective observational study within the Italian Society of Pediatric Research Network included children and adolescents who initiated dupilumab before 18 years of age. Given IEI rarity, we accepted a numerically unbalanced but clinically meaningful cohort. Clinical outcomes were assessed longitudinally using EASI, pruritus NRS, and CDLQI scores. Achievement and maintenance of EASI-50/75/90 re-sponses were evaluated, together with adverse events and treatment discontinuation. Results: Among 127 patients, 116 had polygenic AD and 11 had IEI-associated disease. IEI patients more frequently had disease onset within 6 months (64% vs. 29%; p=0.037), severe recurrent infections (100% vs. 0%; p< 0.001), very elevated sIgE (91% vs. 14%; p< 0.001), and higher baseline EASI (median 50 vs. 25; p< 0.001). EASI, pruritus, and CDLQI improved significantly over time. EASI-50/75/90 were achieved by 88.2%/81.9%/66.1% and maintained by 84.3%/69.3%/47.2%. IEI patients showed steeper EASI decline but achieved EASI-75/90 later. Dupilumab was well tolerated with no unexpected safety signals. Conclusions: Dupilumab provided rapid, sustained improvement across both groups. Despite greater baseline severity and slower deep clearance achievement, IEI patients demonstrated substantial durable benefit, supporting dupilumab use in selected IEI-associated atopic manifestations.
- 7 October 2026
- Published by MDPI AG in Preprints.org
Open AccessUse of Dupilumab in Pediatric Atopic Dermatitis and in Inborn Errors of Immunity-Associated Atopic Skin Disease: An Italian Society of Pediatric Research (SIRP) Multicenter Real-World Study
Background: Atopic dermatitis (AD) is generally considered polygenic but may occur as a predominant manifestation of inborn errors of immunity (IEI). Although dupilumab is effective in pediatric AD, evidence in IEI-associated severe atopic skin disease remains limited, with no longitudinal comparative studies available. We aimed to characterize clinical phenotype and compare effectiveness, quality-of-life, and safety of dupilumab in pediatric patients with severe polygenic AD and IEI-associated severe atopic skin disease. Methods: This multicenter retrospective observational study within the Italian Society of Pediatric Research Network included children and adolescents who initiated dupilumab before 18 years of age. Given IEI rarity, we accepted a numerically unbalanced but clinically meaningful cohort. Clinical outcomes were assessed longitudinally using EASI, pruritus NRS, and CDLQI scores. Achievement and maintenance of EASI-50/75/90 re-sponses were evaluated, together with adverse events and treatment discontinuation. Results: Among 127 patients, 116 had polygenic AD and 11 had IEI-associated disease. IEI patients more frequently had disease onset within 6 months (64% vs. 29%; p=0.037), severe recurrent infections (100% vs. 0%; p< 0.001), very elevated sIgE (91% vs. 14%; p< 0.001), and higher baseline EASI (median 50 vs. 25; p< 0.001). EASI, pruritus, and CDLQI improved significantly over time. EASI-50/75/90 were achieved by 88.2%/81.9%/66.1% and maintained by 84.3%/69.3%/47.2%. IEI patients showed steeper EASI decline but achieved EASI-75/90 later. Dupilumab was well tolerated with no unexpected safety signals. Conclusions: Dupilumab provided rapid, sustained improvement across both groups. Despite greater baseline severity and slower deep clearance achievement, IEI patients demonstrated substantial durable benefit, supporting dupilumab use in selected IEI-associated atopic manifestations.
- Open Access
- 13 May 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1819182
Refractory immune cytopenia successfully treated with mycophenolate mofetil in four adolescents with del22q11.2 syndrome
Introduction: Chromosome 22q11.2 deletion syndrome (22q11DS) presents a wide variability of phenotypic features, including different grades of immune dysfunctions, leading to increased susceptibility to infections, autoimmune diseases and atopy. The most common autoimmune manifestation in 22q11DS patients is immune thrombocytopenia (ITP), which is often relapsing and refractory to standard therapy. Methods: We present a cohort of four pediatric/adolescents 22q11DS patients presenting with refractory ITP, treated with low dosage Mycophenolate Mofetil (MMF) for more than 24 months. We performed complete deep longitudinal immunological investigations by multiparametric flow cytometry, and monitored blood counts as well as EBV viremia. Results: All four patients didn’t experience any relapse since the beginning of MMF therapy. Three out of four showed a complete remission with PLT > 100000/uL. All the patients presented immunological features reported to be associated with immunodysregulation: reduced naïve CD4+T cells and memory B cells, increased cTfh cells and reduced Treg cells frequency. During MMF treatment we detected a decrease in cTfh frequency and a reduction in PD-1 expression along with a moderate recovery of regulatory T cells. Discussion: MMF treatment was associated with sustained platelet stabilization in this cohort. Specific immunological biomarkers could help monitor treatment response, guide clinicians in selecting targeted therapies and may be used to monitor the response to therapy over time.
- 13 May 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1819182
Open AccessRefractory immune cytopenia successfully treated with mycophenolate mofetil in four adolescents with del22q11.2 syndrome
Introduction: Chromosome 22q11.2 deletion syndrome (22q11DS) presents a wide variability of phenotypic features, including different grades of immune dysfunctions, leading to increased susceptibility to infections, autoimmune diseases and atopy. The most common autoimmune manifestation in 22q11DS patients is immune thrombocytopenia (ITP), which is often relapsing and refractory to standard therapy. Methods: We present a cohort of four pediatric/adolescents 22q11DS patients presenting with refractory ITP, treated with low dosage Mycophenolate Mofetil (MMF) for more than 24 months. We performed complete deep longitudinal immunological investigations by multiparametric flow cytometry, and monitored blood counts as well as EBV viremia. Results: All four patients didn’t experience any relapse since the beginning of MMF therapy. Three out of four showed a complete remission with PLT > 100000/uL. All the patients presented immunological features reported to be associated with immunodysregulation: reduced naïve CD4+T cells and memory B cells, increased cTfh cells and reduced Treg cells frequency. During MMF treatment we detected a decrease in cTfh frequency and a reduction in PD-1 expression along with a moderate recovery of regulatory T cells. Discussion: MMF treatment was associated with sustained platelet stabilization in this cohort. Specific immunological biomarkers could help monitor treatment response, guide clinicians in selecting targeted therapies and may be used to monitor the response to therapy over time.
- Open Access
- 24 April 2026
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 22 (1) , 2661495
Pre-vaccination immune signatures of children with inborn errors of immunity associate with COVID-19 vaccine response
The emergence of SARS-CoV-2 in late 2019 led to a global pandemic, prompting unprecedented efforts to develop and deploy effective vaccines.1–3 The BNT162b2 mRNA COVID-19 vaccine has demonstrated h...
- 24 April 2026
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 22 (1) , 2661495
Open AccessPre-vaccination immune signatures of children with inborn errors of immunity associate with COVID-19 vaccine response
The emergence of SARS-CoV-2 in late 2019 led to a global pandemic, prompting unprecedented efforts to develop and deploy effective vaccines.1–3 The BNT162b2 mRNA COVID-19 vaccine has demonstrated h...
- Top Cited PapersOpen Access
- 13 February 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (2)
Lymphoproliferation in inborn errors of immunity: From challenging diagnosis to histologic revision
Inborn errors of immunity (IEI) are genetic disorders that not only heighten infection risk but also disrupt immune regulation, frequently leading to lymphoid tissue overgrowth known as lymphoid proliferations (LPD). We retrospectively reviewed 38 patients with genetically or clinically confirmed IEI and persistent LPD, comparing those with nonneoplastic/reactive hyperplasia to those who developed overt lymphoid neoplasm (lymphoma). Overall, 26% developed lymphoma—predominantly classical Hodgkin lymphoma or diffuse large B cell lymphoma—often after earlier IEI onset. Immunophenotyping and principal component analysis revealed that patients with common variable immunodeficiency developing Hodgkin lymphoma shared a distinctive T cell profile, differing from immunocompetent lymphoma cases. Centralized histologic re-evaluation reclassified several presumed lymphoma as nonneoplastic/reactive hyperplasia and identified Castleman-like and germinal center transformation patterns in nonneoplastic/reactive LPD. Notably, elevated blood IgM and circulating T follicular helper cells mirrored IgM deposits and PD-1+ T cells in lymph nodes. These findings highlight the importance of an integrated approach involving clinical, genetic, and pathological reviews to improve IEI diagnosis and avoid overtreatment.
- 13 February 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (2)
Top Cited PapersOpen AccessLymphoproliferation in inborn errors of immunity: From challenging diagnosis to histologic revision
Inborn errors of immunity (IEI) are genetic disorders that not only heighten infection risk but also disrupt immune regulation, frequently leading to lymphoid tissue overgrowth known as lymphoid proliferations (LPD). We retrospectively reviewed 38 patients with genetically or clinically confirmed IEI and persistent LPD, comparing those with nonneoplastic/reactive hyperplasia to those who developed overt lymphoid neoplasm (lymphoma). Overall, 26% developed lymphoma—predominantly classical Hodgkin lymphoma or diffuse large B cell lymphoma—often after earlier IEI onset. Immunophenotyping and principal component analysis revealed that patients with common variable immunodeficiency developing Hodgkin lymphoma shared a distinctive T cell profile, differing from immunocompetent lymphoma cases. Centralized histologic re-evaluation reclassified several presumed lymphoma as nonneoplastic/reactive hyperplasia and identified Castleman-like and germinal center transformation patterns in nonneoplastic/reactive LPD. Notably, elevated blood IgM and circulating T follicular helper cells mirrored IgM deposits and PD-1+ T cells in lymph nodes. These findings highlight the importance of an integrated approach involving clinical, genetic, and pathological reviews to improve IEI diagnosis and avoid overtreatment.
- Open Access
- 23 June 2025
- Published by Elsevier in Journal of Allergy and Clinical Immunology: Global
- Vol. 4 (4) , 100517
Immune Development in Early Life (IDEaL) longitudinal cohort study protocol: Identifying biomarkers of vaccine responsiveness, respiratory infection, and asthma
- 23 June 2025
- Published by Elsevier in Journal of Allergy and Clinical Immunology: Global
- Vol. 4 (4) , 100517
Open AccessImmune Development in Early Life (IDEaL) longitudinal cohort study protocol: Identifying biomarkers of vaccine responsiveness, respiratory infection, and asthma
- Open Access
- 6 August 2024
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 35 (8) , e14215
Use of dupilumab for atopic dermatitis in pediatric and young adult patients with inborn errors of immunity
- 6 August 2024
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 35 (8) , e14215
Open AccessUse of dupilumab for atopic dermatitis in pediatric and young adult patients with inborn errors of immunity
- Open Access
Characterization of Natural Killer Cell Profile in a Cohort of Infected Pregnant Women and Their Babies and Its Relation to CMV Transmission
Human cytomegalovirus (CMV) is a common herpesvirus causing lifelong latent infection in most people and is a primary cause of congenital infection worldwide. Given the role of NK cells in the materno-fetal barrier, we investigated peripheral blood NK cell behavior in the context of CMV infection acquired during pregnancy. We analyzed the NK phenotype and CD107a surface mobilization on PBMCs from CMV-transmitting and non-transmitting mothers and newborns with or without congenital infection. NK cells from non-transmitting mothers showed the typical phenotype of CMV-adaptive NK cells, characterized by higher levels of NKG2C, CD57, and KIRs, with reduced NKG2A, compared to transmitting ones. A significantly higher percentage of DNAM-1+, PD-1+, and KIR+NKG2A-CD57+PD-1+ CD56dim cells was found in the non-transmitting group. Accordingly, NK cells from congenital-CMV (cCMV)-infected newborns expressed higher levels of NKG2C and CD57, with reduced NKG2A, compared to non-congenital ones. Furthermore, they showed a significant expansion of CD56dim cells co-expressing NKG2C and CD57 or with a memory-like (KIR+NKG2A-CD57+NKG2C+) phenotype, as well as a significant reduction of the CD57-NKG2C- population. Degranulation assays showed a slightly higher CD107a geomean ratio in NK cells of mothers who were non-transmitting compared to those transmitting the virus. Our findings demonstrate that both CMV-transmitting mothers and cCMV newborns show a specific NK profile. These data can guide studies on predicting virus transmission from mothers and congenital infection in infants.
Open AccessCharacterization of Natural Killer Cell Profile in a Cohort of Infected Pregnant Women and Their Babies and Its Relation to CMV Transmission
Human cytomegalovirus (CMV) is a common herpesvirus causing lifelong latent infection in most people and is a primary cause of congenital infection worldwide. Given the role of NK cells in the materno-fetal barrier, we investigated peripheral blood NK cell behavior in the context of CMV infection acquired during pregnancy. We analyzed the NK phenotype and CD107a surface mobilization on PBMCs from CMV-transmitting and non-transmitting mothers and newborns with or without congenital infection. NK cells from non-transmitting mothers showed the typical phenotype of CMV-adaptive NK cells, characterized by higher levels of NKG2C, CD57, and KIRs, with reduced NKG2A, compared to transmitting ones. A significantly higher percentage of DNAM-1+, PD-1+, and KIR+NKG2A-CD57+PD-1+ CD56dim cells was found in the non-transmitting group. Accordingly, NK cells from congenital-CMV (cCMV)-infected newborns expressed higher levels of NKG2C and CD57, with reduced NKG2A, compared to non-congenital ones. Furthermore, they showed a significant expansion of CD56dim cells co-expressing NKG2C and CD57 or with a memory-like (KIR+NKG2A-CD57+NKG2C+) phenotype, as well as a significant reduction of the CD57-NKG2C- population. Degranulation assays showed a slightly higher CD107a geomean ratio in NK cells of mothers who were non-transmitting compared to those transmitting the virus. Our findings demonstrate that both CMV-transmitting mothers and cCMV newborns show a specific NK profile. These data can guide studies on predicting virus transmission from mothers and congenital infection in infants.